37 SUSTAINED VIROLOGIC RESPONSE (SVR) FOLLOWING RG7128 1500MG BID/PEG-IFN/RBV FOR 28 DAYS IN HCV GENOTYPE 2/3 PRIOR NON-RESPONDERS

2010 ◽  
Vol 52 ◽  
pp. S16 ◽  
Author(s):  
E.J. Gane ◽  
M. Rodriguez-Torres ◽  
D.E. Nelson ◽  
I.M. Jacobson ◽  
J.G. McHutchison ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

Sustained Virologic Response to Treatment in 100% of Patients Recently Infected, Nosocomially, With HCV Genotype 2

2008 ◽  
Vol 42 (6) ◽  
pp. 730-733 ◽  
Author(s):  
Emanuel Sikuler ◽  
Ran Tur-Kaspa ◽  
Yonat Shemer-Avni ◽  
Jorge Delgado ◽  
Doron Zilberman ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
Response To Treatment ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

scholarly journals Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

2017 ◽  
Vol 2017 ◽  
pp. 1-4
Author(s):  
Hirokazu Suii ◽  
Itaru Ozeki ◽  
Ryoji Tatsumi ◽  
Masakatsu Yamaguchi ◽  
Mutsuumi Kimura ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Hemolytic Anemia ◽  
Standard Of Care ◽  
Virologic Response ◽  
Hcv Genotype ◽  
Maximum Change ◽  
Genotype 2 ◽  
Ifn Therapy ◽  
Hcv Genotype 2 ◽  
Chronic Hcv

Interferon (IFN) and ribavirin (RBV) combination therapy was previously the standard of care for treatment of hepatitis C virus (HCV) genotype 2 infection. But, it often induced hemolytic anemia. In 2014, sofosbuvir (SOF) was approved for the treatment of chronic HCV genotype 2 in Japan. SOF/RBV therapy is more effective against genotype 2 than IFN/RBV therapy. We report a case of a 74-year-old woman with chronic HCV genotype 2b infection. She received five treatments including RBV and IFN therapy before SOF was approved and all of them were ineffective. Therapies that included RBV induced severe anemia and led to discontinuation of treatment. With pegylated IFN/RBV therapy, the maximum change in hemoglobin (Hb) from baseline was −3.7 g/dL. However, SOF/RBV therapy was effective and she achieved sustained virologic response (SVR) with a maximum change in Hb from baseline of only −1.2 g/dL. We also found reticulocyte count was very low during treatment in this case and speculate it was one of the reasons that she developed hemolytic anemia with RBV. In conclusion, SOF/RBV therapy is effective and allowed the patient to achieve SVR. An SOF/RBV regimen is safe and effective for patients who have or are at risk of anemia induced by RBV.

Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)

2013 ◽  
Vol 58 (3) ◽  
pp. 445-451 ◽  
Author(s):  
Oliver Lenz ◽  
Leen Vijgen ◽  
Jan Martin Berke ◽  
Maxwell D. Cummings ◽  
Bart Fevery ◽  
...  
Keyword(s):  
Virologic Response ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

THE IMPORTANCE OF ANTI-HCV SCREENING IN PATIENTS OF LARGE MULTIFIELD HOSPITALS

2020 ◽  
Author(s):  
E.N. Kudrjavtseva ◽  
◽  
M.I. Korabelnikova ◽  
T.A. Semenenko ◽  
Ya.V. Panasyuk ◽  
...  
Keyword(s):  
Men And Women ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2 ◽  
Hcv Screening ◽  
Subtype 1B

In the studied cohort, HCV subtypes 1b and 3a prevailed — 47,7% and 38,9%, respectively HCV genotype 2 was detected in 7,2% of cases and HCV subtype 1a — in 5,8% of cases. HCV genotype was not determined in 0,4% of patients. Difference between a frequency of detection of subtypes 1b and 3a of HCV in men and women were recorded. Subtype 3a HCV was determined in men in 44,8% of cases, and in women — in 31,7% of cases (p < 0.01). HCV subtype 1b in women was determined with a higher frequency (55,0%, р < 0, 01), than in men (41,8%).

S2071 In HIV-HCV Co-Infected Patients with HCV Genotype 2 or 3 Infection a 6-Month Treatment with Peginterferon Alpha Plus Ribavirin Has the Same Efficacy As in Mono-Infected Patients

2009 ◽  
Vol 136 (5) ◽  
pp. A-324
Author(s):  
Jean-Jacques Gonvers ◽  
Markus H. Heim ◽  
Matthias Cavassini ◽  
Beat Müllhaupt ◽  
Daniel Genné ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

2015 ◽  
Vol 148 (2) ◽  
pp. 355-366.e1 ◽  
Author(s):  
Gregory J. Dore ◽  
Eric Lawitz ◽  
Christophe Hézode ◽  
Stephen D. Shafran ◽  
Alnoor Ramji ◽  
...  
Keyword(s):  
Duration Of Treatment ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2 ◽  
Peginterferon And Ribavirin
Sign in / Sign up

Export Citation Format

Share Document